{"prompt": "['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'at risk through study participation, or which would affect the safety analysis or other', 'analysis if the disease/condition exacerbated during the study.', '9. History of sensitivity to any of the study medications, or components thereof or a', 'history of drug or other allergy that, in the opinion of the investigator of GSK medical', 'monitor, contraindicates their participation.', '10. Current or chronic history of liver disease, or known hepatic or biliary abnormalities', \"(with the exception of Gilbert's syndrome or asymptomatic gallstones).\", '11. Abnormal and clinically significant 12-lead ECG finding. The investigator will', 'determine the clinical significance of each abnormal ECG finding in relation to the', \"subject's medical history and exclude participants who would be at undue risk by\", 'participating in the trial. An abnormal and clinically significant finding that would', 'preclude a subject from entering the trial is defined as a 12-lead tracing that is', 'interpreted as, but not limited to, any of the following:', '- AF with rapid ventricular rate > 120 bpm;', '- sustained or non-sustained VT', '- second degree heat block Mobitz type II and third degree heart block (unless', 'pacemaker or defibrillator has been implanted)', '- QTcF 500 msec in patients with QRS < 120 msec and QTcF 530 msec in', 'patients with QRS > 120 msec', '12. Previous lung surgery (e.g. lobectomy, pneumonectomy) or lung volume reduction', 'procedure.', 'Prior/Concomitant Therapy', '13. Current or expected chronic use of macrolide antibiotics during the study period for', 'the prevention of COPD exacerbations. Examples of chronic use include, but are not', 'limited to, daily or two to three times per week use for at least 3 months.', '14. Oral or injectable CYP3A4 or BRCP (breast cancer resistance protein) substrates with', 'a narrow therapeutic index (CYP3A4 substrates include, but are not limited to,', 'alfenatil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide,', 'quinidine, sirolimus, tacrolimus, and theophylline; BCRP substrates include, but are', 'not limited to, topotecan.) The Investigator should consult with the Medical Monitor', 'if necessary.', '15. Current or expected use of phosphodiesterase-4 inhibitors (e.g. roflumilast).', 'Participants currently receiving roflumilast may be included if they are able to', 'discontinue use from 30 days prior to screening through the completion of the follow', 'up visit.', 'Prior/Concurrent Clinical Study Experience', '16. Participation in a previous clinical trial and has received an investigational product', 'within any of the following time periods prior to the first dosing day in the current', '26']['2016N293064_02', 'CONFIDENTIAL', '2018N394263_00', '205864', 'study: 30 days, 5 half lives, or twice the duration of the biological effect of the', 'investigational product (whichever is longer).', '17. Participation in a previous clinical trial with danirixin within 1 year prior to the first', 'dosing day in the current study', '18. Exposure to more than four investigational products within 1 year prior to the first', 'dosing day in the current study.', 'Diagnostic assessments', '19. Alanine transferase (ALT) > 2x upper limit of normal (ULN); bilirubin > 1.5xULN', '(isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct', 'bilirubin <35%).', '20. A positive test for HIV antibody.', '21. A positive pre-study hepatitis B surface antigen or positive hepatitis C antibody result', 'within 3 months prior to screening.', 'Other Exclusions', '22. Pulmonary rehabilitation: Participants who have taken part in the acute phase of a', 'pulmonary rehabilitation program within 4 weeks prior to screening or participants', 'who plan to enter the acute phase of a pulmonary rehabilitation program during the', 'study. Participants who are in the maintenance phase of a pulmonary rehabilitation', 'program are not excluded.', '23. A history of allergy or hypersensitivity to any of the ingredients in the study', 'treatment.', '24. A known or suspected history of alcohol or drug abuse within the 2 years prior to', 'screening.', '25. Inability to read: in the opinion of the Investigator, any participant who is unable to', 'read and/or would not be able to complete study related materials.', '26. Affiliation with the study site: study investigators, sub-investigators, study', 'coordinators, employees of a study investigator, sub-investigator or study site, or', 'immediate family member of any of the above that are involved with the study.', '6.3.', 'Lifestyle Restrictions', '6.3.1.', 'Meals and Dietary Restrictions', 'No meal or dietary restrictions are required for participation in this study. Danirixin must', 'be taken with food. Specific dosing instructions will be provided in the Study Reference', 'Manual (SRM) and will be provided to all study participants.', '6.3.2.', 'Activity', 'Participants should abstain from strenuous exercise for 24 hours before each blood', 'collection for clinical laboratory tests.', '27']\n\n###\n\n", "completion": "END"}